Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3533-3537

  Sime, Fekade Bruck ^a,b   Roberts, Michael S ^a,b   Warner, Morgyn S ^c   Hahn, Uwe ^b   Robertson, Thomas A ^a,b   Yeend, Sue ^b   Phay, Andy ^b   Lehman, Sheila ^b   Lipman, Jeffrey ^d,e   Peake, Sandra L ^b   Roberts, Jason A ^a,d,e  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; PIPERACILLIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXPOSURE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE MYELOMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; COMPLICATION; FEVER; HEMATOLOGIC DISEASE; MIDDLE AGED; NEUTROPENIA;

AGED; ANTI-BACTERIAL AGENTS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PIPERACILLIN;

EID: 84901279363     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02340-14     Document Type: Article

References (29)

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. 2005. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916-1924. http://dx.doi.org/10.1002/cncr.20983.
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34:730-751. http://dx.doi.org/10.1086/339215.
3. Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C, Club de Reflexion sur les Infections en Onco-Hématologie. 2008. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect. Dis. 8:612-620. http://dx.doi.org/10. 1016/S1473-3099(08)70228-7.
4. Theuretzbacher U. 2012. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin. Infect. Dis. 54: 1785-1792. http://dx.doi.org/10.1093/cid/cis210.
5. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96. http://dx.doi.org/10. 1016/0732-8893(95)00053-D.
6. Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M. 2005. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob. Agents Chemother. 49:3550-3553. http://dx.doi.org/10.1128/ AAC.49.8.3550-3553.2005.
7. Nyhlén A, Ljungberg B, Nilsson-Ehle I. 1997. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group. Eur. J. Clin. Microbiol. Infect. Dis. 16:797-802. http://dx.doi.org/10.1007/BF01700408.
8. Drusano GL, de Jongh C, Newman K, Joshi J, Wharton R, Moody MR, Schimpff SC. 1985. Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients. Infection 13:20-26. http://dx.doi.org/10. 1007/BF01643616.
9. Drusano GL, Forrest A, Plaisance KI, Wade JC. 1989. A prospective evaluation of optimal sampling theory in the determination of the steadystate pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin. Pharmacol. Ther. 45:635-641. http://dx.doi.org/10.1038/clpt.1989.84.
10. Zhang Y, Huo M, Zhou J, Xie S. 2010. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 99:306-314. http://dx.doi.org/10.1016/j.cmpb.2010.01. 007.
11. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA. 2013. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob. Agents Chemother. 57:6165-6170. http://dx.doi.org/10.1128/AAC.00951-13.
12. EUCAST. 2013. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST- files/Breakpoint-tables/Breakpoint-table-v-3.1.pdf.
13. CLSI. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Maeda H. 2012. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 88:53-71. http://dx.doi.org/10.2183/pjab.88.53.
15. Theuretzbacher U, Zeitlinger M. 2011. Antibacterial distribution and drug-drug interactions in cancer patients, p 443-454. In Safdar A (ed), Principles and practice of cancer infectious diseases. Springer Science Business Media, New York, NY.
16. Roy AC, Jones DN, Slavotinek JP, Kichenadasse G, Karapetis C, Lam E, Bishnoi S, Koczwara B. 2011. Very high GFR in cancer patients undergoing chemotherapy: prevalence, carboplatin dosing patterns and chemotherapy toxicity. Asia Pac. J. Clin. Oncol. 7:281-286. http://dx.doi.org/10.1111/j.1743-7563. 2011.01409.x.
17. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. 2010. Augmented renal clearance in the intensive care unit: an illustrative case series. Int. J. Antimicrob. Agents 35:606-608. http://dx.doi.org/10.1016/j.ijantimicag.2010.02. 013.
18. Chacko J. 2013. Assessment of renal function in the critically ill-shall we look beyond predictive equations? Indian J. Crit. Care Med. 17:65-66. http://dx.doi.org/10.4103/0972-5229.114814.
19. Star RA. 1998. Treatment of acute renal failure. Kidney Int. 54:1817-1831. http://dx.doi.org/10.1046/j.1523-1755.1998.00210.x.
20. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300. http://dx.doi.org/10.1038/ nrmicro862.
21. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. 2005. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39:32-38. http://dx.doi.org/10.1345/aph.1E271.
22. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22. http://dx.doi.org/10.1086/514622.
23. Gerber AU, Brugger HP, Feller C, Stritzko T, Stalder B. 1986. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J. Infect. Dis. 153:90-97. http://dx.doi.org/10.1093/infdis/153.1.90.
24. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF. 1986. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob. Agents Chemother. 30:403-408. http://dx.doi.org/10.1128/AAC.30.3. 403.
25. Casal J, Giménez MJ, Aguilar L, Yuste J, Jado I, Tarrago D, Fenoll A. 2002. Beta-lactam activity against resistant pneumococcal strains is en-hanced by the immune system. J. Antimicrob. Chemother. 50(Suppl S2): 83-86. http://dx.doi.org/10.1093/jac/dkf502.
26. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M. 2010. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit. Care Med. 38: 1045-1053. http://dx.doi.org/ 10.1097/CCM.0b013e3181cc4824.
27. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. 2002. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob. Agents Chemother. 46:854-858. http://dx.doi.org/10.1128/AAC.46.3.854-858.2002.
28. Abbott IJ, Roberts JA. 2012. Infusional-lactam antibiotics in febrile neutropenia: has the time come? Curr. Opin. Infect. Dis. 25:619-625. http://dx.doi.org/10.1097/QCO.0b013e32835915c2.
29. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. 2010. Therapeutic drug monitoring of betalactams in critically ill patients: proof of concept. Int. J. Antimicrob. Ag. 36:332-339. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.008.